Medicare Payment Relief For CAR-T Limited To Higher Add-On Payments In 2020

US Centers for Medicare and Medicaid Services concludes structural changes to existing payment systems to accommodate the high cost of Novartis’ Kymriah and Gilead’s Yescarta are still “premature.”

Medicare word cloud
Medicare Add-On Payments For CAR-T Will Total $94m

Medicare payments to hospitals treating cancer patients with Novartis AG’ Kymriah (tisagenlecleucel) and Gilead Sciences Inc.’s Yescarta (axicabtagene ciloleucel) will not increase significantly in 2020 despite requests from manufacturers, providers and other advocates, which argue that access to the treatment is currently challenged by inadequate reimbursement.

In its 2020 Medicare payment update final rule for hospital inpatient services and technologies, released 2 July, the Centers...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet